Company Description
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea.
The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.
In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Kuk Hwang |
Contact Details
Address: 10900 NE 4th Street, Suite 2300 Bellevue, Washington 98004 United States | |
| Phone | 425 635 7700 |
| Website | osr-holdings.com |
Stock Details
| Ticker Symbol | OSRH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840425 |
| ISIN Number | US68840D1028 |
| Employer ID | 84-5052822 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kuk Hyoun Hwang | Chairman and Chief Executive Officer |
| Gihyoun Bang | Chief Financial Officer |
| Dr. Constance Hofer | Chief Scientific Officer |
| Jun Chul Whang | Chief Legal Officer, Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2025 | 8-K | Current Report |
| Sep 9, 2025 | 8-K | Current Report |
| Sep 9, 2025 | 8-K | Current Report |
| Aug 29, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 19, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 2, 2025 | 8-K | Current Report |